Additionally, overexpression of hnRNPA2B1 resulted in increased half maximal inhibitory concentration (IC50) values, indicating that hnRNPA2B1 overexpression significantly reduced the sensitivity of GC cells to cisplatin (CDDP) treatment (Figure S4, Supporting Information). Here, HNRNPA2B1 is linked to gastric cancer.